NASDAQ:MCRB

Seres Therapeutics Q2 2026 Earnings Results & Report

Seres Therapeutics logo
$1.44 +0.03 (+2.13%)
Closing price 04:00 PM Eastern
Extended Trading
$1.43 -0.01 (-0.62%)
As of 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Seres Therapeutics beat analyst expectations on both earnings and revenue in its Q2 2026 results, released August 5, 2026. The company reported EPS of $0.47 versus the -$2.18 consensus estimate, while revenue of $736 thousand topped the $179 thousand estimate by $557.00 thousand.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Seres Therapeutics EPS Results

Actual EPS
$0.47
Consensus EPS
-$2.18
Beat/Miss
Beat by +$2.65
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Seres Therapeutics Revenue Results

Actual Revenue
$736 thousand
Expected Revenue
$179 thousand
Beat/Miss
Beat by +$557.00 thousand
YoY Revenue Growth
N/A

Seres Therapeutics Q2 2026 Earnings FAQ

Seres Therapeutics (NASDAQ:MCRB) reported earnings of $0.47 per share for Q2 2026, beating the consensus estimate of -$2.18. The report was announced on Wednesday, August 5, 2026.

Seres Therapeutics reported revenue of $736 thousand for Q2 2026, against a consensus estimate of $179 thousand.

Seres Therapeutics Earnings Headlines

Equities Analysts Set Expectations for MCRB FY2026 Earnings
Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
Seres Therapeutics: Q3 earnings snapshot
See More Seres Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Seres Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Seres Therapeutics and other key companies, straight to your email.

About Seres Therapeutics

Seres Therapeutics (NASDAQ:MCRB) is a biotechnology company based in Cambridge, Massachusetts, focused on developing microbiome-based medicines. Its approach uses live biotherapeutic products designed to influence the gut microbiome and address conditions including infections and complications associated with impaired immune function.

The company developed VOWST, an oral microbiota-based therapy approved in the United States to prevent recurrent Clostridioides difficile infection in adults after antibacterial treatment. Seres developed the product in collaboration with Nestlé Health Science, which acquired rights to VOWST.

Seres has also advanced investigational candidates such as SER-155, an oral live biotherapeutic being studied for potential use in people at risk of infections related to immune suppression. The company’s research builds on its work in microbiome science and therapeutic development.

View Seres Therapeutics Profile